X

Xenon Pharmaceuticals Inc
F:XP0

Watchlist Manager
Xenon Pharmaceuticals Inc
F:XP0
Watchlist
Price: 27.6 EUR 1.47% Market Closed
Market Cap: 2.1B EUR

Intrinsic Value

XP0's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one XP0 stock under the Base Case scenario is 6.07 EUR. Compared to the current market price of 27.6 EUR, Xenon Pharmaceuticals Inc is Overvalued by 78%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

XP0 Intrinsic Value
6.07 EUR
Overvaluation 78%
Intrinsic Value
Price
X
Worst Case
Base Case
Best Case

Valuation History
Xenon Pharmaceuticals Inc

Valuation History Unavailable

Historical valuation for XP0 cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare XP0 to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about XENE?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Xenon Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Xenon Pharmaceuticals Inc

Current Assets 565.5m
Cash & Short-Term Investments 549.6m
Receivables 8.6m
Other Current Assets 7.3m
Non-Current Assets 177.7m
Long-Term Investments 141.5m
PP&E 17.3m
Other Non-Current Assets 18.9m
Efficiency

Free Cash Flow Analysis
Xenon Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Xenon Pharmaceuticals Inc

Revenue
7.5m USD
Operating Expenses
-300.5m USD
Operating Income
-293m USD
Other Expenses
41.5m USD
Net Income
-251.4m USD
Fundamental Scores

XP0 Profitability Score
Profitability Due Diligence

Xenon Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

15/100
Profitability
Score

Xenon Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

XP0 Solvency Score
Solvency Due Diligence

Xenon Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Xenon Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

XP0 Price Targets Summary
Xenon Pharmaceuticals Inc

Wall Street analysts forecast XP0 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XP0 is 49.17 EUR with a low forecast of 37.35 EUR and a high forecast of 60.09 EUR.

Lowest
Price Target
37.35 EUR
35% Upside
Average
Price Target
49.17 EUR
78% Upside
Highest
Price Target
60.09 EUR
118% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Xenon Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for XENE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

XENE Insider Trading
Buy and sell transactions by insiders

XP0 News

Other Videos
What is the Intrinsic Value of one XP0 stock?

The intrinsic value of one XP0 stock under the Base Case scenario is 6.07 EUR.

Is XP0 stock undervalued or overvalued?

Compared to the current market price of 27.6 EUR, Xenon Pharmaceuticals Inc is Overvalued by 78%.

Back to Top